354 related articles for article (PubMed ID: 20337586)
1. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
Holscher C
Recent Pat CNS Drug Discov; 2010 Jun; 5(2):109-17. PubMed ID: 20337586
[TBL] [Abstract][Full Text] [Related]
2. RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes.
Gault VA
Diabet Med; 2018 Jan; 35(1):33-40. PubMed ID: 29044772
[TBL] [Abstract][Full Text] [Related]
3. Incretin hormone mimetics and analogues in diabetes therapeutics.
Green BD; Flatt PR
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):497-516. PubMed ID: 18054732
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease.
Ji C; Xue GF; Li G; Li D; Hölscher C
Rev Neurosci; 2016 Jan; 27(1):61-70. PubMed ID: 26351802
[TBL] [Abstract][Full Text] [Related]
5. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
Hölscher C
Sheng Li Xue Bao; 2014 Oct; 66(5):497-510. PubMed ID: 25331995
[TBL] [Abstract][Full Text] [Related]
6. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.
Hölscher C
Br J Pharmacol; 2022 Feb; 179(4):695-714. PubMed ID: 33900631
[TBL] [Abstract][Full Text] [Related]
7. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
[TBL] [Abstract][Full Text] [Related]
8. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
9. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.
Zhang ZQ; Hölscher C
Peptides; 2020 Mar; 125():170184. PubMed ID: 31705913
[TBL] [Abstract][Full Text] [Related]
10. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.
Hölscher C
Alzheimers Dement; 2014 Feb; 10(1 Suppl):S47-54. PubMed ID: 24529525
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
13. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
Hunter K; Hölscher C
BMC Neurosci; 2012 Mar; 13():33. PubMed ID: 22443187
[TBL] [Abstract][Full Text] [Related]
14. Incretins yesterday, pleiotropic gastrointestinal hormones today:glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Kiec-Klimczak ME; Pach DM; Pogwizd ME; Hubalewska-Dydejczyk AB
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):176-82. PubMed ID: 21913887
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
McClean PL; Gault VA; Harriott P; Hölscher C
Eur J Pharmacol; 2010 Mar; 630(1-3):158-62. PubMed ID: 20035739
[TBL] [Abstract][Full Text] [Related]
16. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.
Mentis N; Vardarli I; Köthe LD; Holst JJ; Deacon CF; Theodorakis M; Meier JJ; Nauck MA
Diabetes; 2011 Apr; 60(4):1270-6. PubMed ID: 21330636
[TBL] [Abstract][Full Text] [Related]
17. Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells.
Jalewa J; Sharma MK; Hölscher C
J Neurochem; 2016 Oct; 139(1):55-67. PubMed ID: 27412483
[TBL] [Abstract][Full Text] [Related]
18. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
Hölscher C
Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
[TBL] [Abstract][Full Text] [Related]
19. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Green BD; Gault VA; O'harte FP; Flatt PR
Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
